NASDAQ$MBRX
Moleculin Biotech Inc · Q4 2022 earnings
Q4 2022 earnings · · Investor relations
Briefing
Reported financial results for the full year 2022 and provided a pipeline update.
Moleculin Biotech reported its full year 2022 financial results, highlighting progress in clinical and preclinical development programs and sufficient capital to fund operations into the third quarter of 2024.
- Announced the publication of data evaluating Annamycin's performance as an anthracycline in the European Journal of Cancer.
- Received approval in Italy and dosed first subjects for Phase 1/2 trial evaluating Annamycin in combination with cytarabine for AML treatment.
- Announced final topline successful safety data and reported 80% overall response rate in final cohort from the European Phase 1 trial evaluating Annamycin as a single agent treatment of Refractory AML.
- Granted Fast Track Designation from the FDA of WP1122 for the treatment of Glioblastoma Multiforme (GBM).
Headline financials
Revenue & EPS history
Moleculin · Revenue · Quarterly
$0
Historical earnings impact
How earnings announcements have historically affected this stock's price.
Avg. return before/after earnings
Based on 18 quarterly earnings reports · overlaid with Q4 2022
-1.3%
Avg return
Earnings day
-1.3%
Avg return
5 days after
-5.3%
Avg return
30 days after
33%
13 / 40 earnings
Positive
+28.1%
Q4 2019
Best reaction
-20.8%
Q4 2023
Worst reaction
| Quarter | Report date | Reaction (Day 0) | +5 days | +30 days |
|---|---|---|---|---|
| Q4 2025 | — | — | — | |
| Q1 2026 | +2.8% | +9.8% | — | |
| Q3 2025 | -4.4% | -3.5% | -56.1% | |
| Q2 2025 | -4.0% | -11.7% | -46.1% | |
| Q1 2025 | -8.2% | -1.3% | -35.3% | |
| Q4 2024 | -2.8% | -3.7% | -12.8% | |
| Q3 2024 | +3.5% | +6.3% | +3.9% | |
| Q2 2024 | -5.1% | +2.1% | +3.4% | |
| Q1 2024 | +1.9% | +6.7% | -9.2% | |
| Q4 2023 | -20.8% | -16.4% | -29.9% | |
| Q3 2023 | +1.9% | +9.3% | -2.4% | |
| Q2 2023 | -1.3% | -7.5% | -32.7% | |
| Q1 2023 | -14.4% | -21.7% | -23.1% | |
| Q4 2022 | -1.9% | -7.8% | -24.0% | |
| Q3 2022 | +5.1% | +6.1% | +48.6% | |
| Q2 2022 | +9.3% | +3.7% | -12.3% | |
| Q1 2022 | +1.6% | +9.0% | +23.0% | |
| Q4 2021 | -4.4% | -1.7% | +1.1% | |
| Q3 2021 | +0.0% | -6.5% | -5.7% | |
| Q2 2021 | -3.3% | -11.1% | -0.3% | |
| Q1 2021 | -3.8% | -2.6% | +13.2% | |
| Q4 2020 | -1.5% | -6.6% | -99.8% | |
| Q3 2020 | +2.9% | +8.5% | +14.1% | |
| Q2 2020 | -7.4% | -5.6% | -29.0% | |
| Q1 2020 | +0.0% | +0.0% | +11.2% | |
| Q4 2019 | +28.1% | +27.9% | +155.9% | |
| Q3 2019 | +0.9% | -0.9% | -4.7% | |
| Q2 2019 | +6.5% | +10.2% | +13.0% | |
| Q1 2019 | -0.8% | -5.7% | -4.9% | |
| Q4 2018 | +3.8% | -1.5% | -0.8% | |
| Q3 2018 | -3.1% | +6.1% | -3.8% | |
| Q2 2018 | +0.0% | -1.2% | +0.0% | |
| Q1 2018 | -0.6% | -0.6% | +12.1% | |
| Q4 2017 | -3.2% | -1.1% | -0.5% | |
| Q3 2017 | -0.4% | +3.7% | +5.6% | |
| Q2 2017 | -7.7% | -11.8% | -3.7% | |
| Q1 2017 | -4.7% | -4.9% | +0.0% | |
| Q4 2016 | -12.8% | -28.2% | -27.4% | |
| Q3 2016 | -2.4% | +1.7% | -50.5% | |
| Q2 2016 | -1.6% | -6.7% | -1.0% | |
| Q1 2016 | +2.3% | +5.4% | +5.2% | |
| Q3 2015 | — | — | — |
Discussion
Share your read of this quarter. Sign-in carries your eToro identity.
Join the conversation
Sign in with eToro to post your read of this quarter and vote on others'.
Sign in with eToro